product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human Fc gamma RIIIA/CD16a Protein, CF
catalog :
4325-FC-050
quantity :
50 ug
price :
405 USD
more info or order :
R&D Systems product webpage
citations: 18
Reference
Noy Porat T, Edri A, Alcalay R, Makdasi E, Gur D, Aftalion M, et al. Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies. Antibodies (Basel). 2021;10: pubmed publisher
Kitanaga Y, Yamajuku D, Kubo S, Nakamura K, Maeda M, Seki M, et al. Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. Int Immunopharmacol. 2021;101:108343 pubmed publisher
Vanhove B, Duvaux O, Rousse J, Royer P, Evanno G, Ciron C, et al. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2. Eur J Immunol. 2021;51:1412-1422 pubmed publisher
Domján J, Vass P, Hirsch E, Szabó E, Pantea E, Andersen S, et al. Monoclonal antibody formulation manufactured by high-speed electrospinning. Int J Pharm. 2020;591:120042 pubmed publisher
Blundell P, Lu D, Wilkinson M, Dell A, Haslam S, Pleass R. Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus. J Immunol. 2019;202:1595-1611 pubmed publisher
Wozniak Knopp G, Stadlmayr G, Perthold J, Stadlbauer K, Gotsmy M, Becker S, et al. An antibody with Fab-constant domains exchanged for a pair of CH3 domains. PLoS ONE. 2018;13:e0195442 pubmed publisher
Arce Vargas F, Furness A, Litchfield K, Joshi K, Rosenthal R, Ghorani E, et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. 2018;33:649-663.e4 pubmed publisher
Lee C, Jeong M, Lee J, Seo S, Cho S, Zhang W, et al. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. MAbs. 2017;9:968-977 pubmed publisher
Le Clorennec C, BAZIN H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, et al. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3. Mol Cancer Ther. 2017;16:1312-1323 pubmed publisher
Lohse S, Meyer S, Meulenbroek L, Jansen J, Nederend M, Kretschmer A, et al. An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Res. 2016;76:403-17 pubmed publisher
Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis H, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822-31 pubmed publisher
Anikeeva N, Steblyanko M, Fayngerts S, Kopylova N, Marshall D, Powers G, et al. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur J Immunol. 2014;44:2331-9 pubmed publisher
Xie J, Yamniuk A, Borowski V, Kuhn R, Susulic V, Rex Rabe S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192:4083-92 pubmed publisher
Lajoie L, Congy Jolivet N, Bolzec A, Gouilleux Gruart V, Sicard E, Sung H, et al. ADAM17-mediated shedding of Fc?RIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol. 2014;192:741-51 pubmed publisher
Franco A, Damdinsuren B, Ise T, Dement Brown J, Li H, Nagata S, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol. 2013;190:5739-46 pubmed publisher
Boltz A, Piater B, Toleikis L, Guenther R, Kolmar H, Hock B. Bi-specific aptamers mediating tumor cell lysis. J Biol Chem. 2011;286:21896-905 pubmed publisher
von Horsten H, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K, et al. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology. 2010;20:1607-18 pubmed publisher
Wei Y, Li C, Huang W, Li B, Strome S, Wang L. Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. Biochemistry. 2008;47:10294-304 pubmed publisher
image
image 1 :
R&D Systems 4325-FC-050 image 1
Recombinant Human Fc gamma RIIIA/CD16a Protein Binding Activity
product information
brand :
R&D Systems
master code :
4325-FC
SKU :
4325-FC-050
product name :
Recombinant Human Fc gamma RIIIA/CD16a Protein, CF
description :
The Recombinant Human Fc gamma RIIIA/CD16a Protein, CF from R&D Systems is derived from NS0. The Recombinant Human Fc gamma RIIIA/CD16a Protein, CF has been validated for the following applications: Binding Activity.
target :
Fc gamma RIIIA/CD16a
category :
Proteins and Enzymes
sizes available :
50 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain
species :
Human
observed molecular weight :
40-50 kDa, reducing conditions
theoretical molecular weight :
22.6 kDa
gene symbol :
FCGR3A
details of functionality :
Measured by its ability to bind human IgG with an estimated Kd 50 nM.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
AAH17865
applications :
Binding Activity
extended description :
Isoform V176, His-tag
source :
NS0-derived Recombinant Human Fc gamma RIIIA/CD16a Protein, CF
USD :
399
USD 2023 :
405 USD
product details :
Isoform V176, His-tag
alt names :
CD16a, CD16a antigen, CD16FCRIIIA, Fc fragment of IgG, low affinity IIIa, receptor (CD16a), Fc fragment of IgG, low affinity IIIa, receptor for (CD16), Fc gamma receptor III-A, FCG3, Fc-gamma receptor III-2 (CD 16), Fc-gamma receptor IIIb (CD16), Fc-gamma RIII, Fc-gamma RIIIa, Fc-gamma RIII-alpha, FCGR3, FCGR3A, FCGRIII, FcgRIIIA, FCR-10, FcRIII, FcRIIIa, IGFR3FcgammaRIIIA, immunoglobulin G Fc receptor III, low affinity III, receptor for (CD16), low affinity immunoglobulin gamma Fc region receptor III-A, neutrophil-specific antigen NA
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.